RT Journal Article
SR Electronic
T1 Severe COVID-19 Is Fueled by Disrupted Gut Barrier Integrity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.13.20231209
DO 10.1101/2020.11.13.20231209
A1 Leila B. Giron
A1 Harsh Dweep
A1 Xiangfan Yin
A1 Han Wang
A1 Mohammad Damra
A1 Aaron R. Goldman
A1 Nicole Gorman
A1 Clovis S. Palmer
A1 Hsin-Yao Tang
A1 Maliha W. Shaikh
A1 Christopher B. Forsyth
A1 Robert A. Balk
A1 Netanel F Zilberstein
A1 Qin Liu
A1 Andrew Kossenkov
A1 Ali Keshavarzian
A1 Alan Landay
A1 Mohamed Abdel-Mohsen
YR 2020
UL http://medrxiv.org/content/early/2020/11/16/2020.11.13.20231209.abstract
AB A disruption of the crosstalk between gut microbiota and the lung (gut-lung axis) has been implicated as a driver of severity during respiratory-related diseases. Lung injury causes systemic inflammation, which disrupts gut barrier integrity, increasing the permeability to gut microbes and their products. This exacerbates inflammation, resulting in positive feedback. To test the possibility that a disrupted gut contributes to Coronavirus disease 2019 (COVID-19) severity, we used a systems biology approach to analyze plasma from COVID-19 patients with varying disease severity and controls. Severe COVID-19 is associated with a dramatic increase in tight junction permeability and translocation of bacterial and fungal products into blood. This intestinal disruption and microbial translocation correlate strongly with increased systemic inflammation and complement activation, lower gut metabolic function, and higher mortality. Our study highlights a previously unappreciated factor with significant clinical implications, disruption in gut barrier integrity, as a force that contributes to COVID-19 severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by a supplement to R01 DK123733 (R01 DK123733-01S1) for M.A-M, A.L, and A.Ke and R24 AA026801- 02S1 for A.Ke. M.A-M is also supported by The Foundation for AIDS Research (amfAR) impact grant # 109840-65-RGR, NIH grants (R01 AG062383, R01NS117458, R21 AI143385, R21 AI129636, and R21 NS106970), and the Penn Center for AIDS Research (P30 AI 045008). The Wistar Proteomics and Metabolomics Shared Resource is supported in part by NIH Cancer Center Support Grant CA010815. The Thermo Q-Exactive HF-X mass spectrometer was purchased with NIH grant S10 OD023586.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All research protocols of the study were approved by the institutional review boards (IRB) at Rush University and The Wistar Institute. All human experimentation was conducted in accordance with the guidelines of the US Department of Health and Human Services and those of the authors institutions.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript or upon request.